Royalty Pharma plc
RPRX
$60.85
-$1.07-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 10.01% | 7.80% | 5.06% | 3.70% | 3.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.01% | 7.80% | 5.06% | 3.70% | 3.02% |
| Cost of Revenue | 126.85% | -1,785.85% | -140.39% | -131.49% | -139.60% |
| Gross Profit | -10.00% | 25.18% | 74.65% | 41.19% | 117.56% |
| SG&A Expenses | 29.76% | 148.93% | 185.68% | 142.74% | 115.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 118.71% | 119.10% | -14.30% | 10.94% | -64.80% |
| Operating Income | -16.33% | -13.48% | 19.61% | 0.31% | 93.25% |
| Income Before Tax | -19.06% | -23.09% | -0.27% | -23.83% | 61.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.06% | -23.09% | -0.27% | -23.83% | 61.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 16.95% | 21.34% | -17.26% | 5.50% | -80.64% |
| Net Income | -20.39% | -24.17% | -9.90% | -32.94% | 52.06% |
| EBIT | -16.33% | -13.48% | 19.61% | 0.31% | 93.25% |
| EBITDA | 590.71% | -- | -- | 6.61% | -70.61% |
| EPS Basic | -19.45% | -23.09% | -7.06% | -35.71% | 45.68% |
| Normalized Basic EPS | -35.60% | -17.75% | 16.63% | 3.60% | 195.06% |
| EPS Diluted | -19.37% | -23.12% | -7.31% | -35.88% | 45.49% |
| Normalized Diluted EPS | -35.25% | -17.77% | 10.46% | 11.19% | 212.34% |
| Average Basic Shares Outstanding | -1.37% | -3.90% | -4.62% | 4.83% | 5.66% |
| Average Diluted Shares Outstanding | -4.00% | -5.18% | -5.05% | -4.01% | -2.96% |
| Dividend Per Share | 5.81% | 5.29% | 4.76% | 4.82% | 4.88% |
| Payout Ratio | 0.33% | 0.35% | 0.12% | 0.51% | -0.33% |